Compass Therapeutics (CMPX) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 2.4% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -94.7% for STRO. Sutro Biopharma is the larger company by market cap ($142.8 million vs $123.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | STRO |
|---|---|---|
| Share price | $0.6882 | $8.60 |
| Market cap | $123.94M | $142.77M |
| 1-day change | +1.43% | -1.38% |
| YTD return | -87.18% | -25.67% |
| 1-year return | -85.87% | +2.38% |
| 5-year return | -78.63% | -94.68% |
| EPS (TTM) | $-0.46 | $-12.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $102.48M |
| Revenue growth (YoY) | -100.00% | +65.18% |
| Net income (latest FY) | $-66.49M | $-191.09M |
| Operating margin | — | -154.53% |
| Net margin | — | -186.45% |
| 52-week high | $6.88 | $43.85 |
| 52-week low | $0.57 | $7.15 |
| Distance from 52-week high | -90.00% | -80.39% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +664.31% | +419.65% |
| Average volume | 3.88M | 304.90K |
| Shares outstanding | 180.09M | 16.60M |
| Employees | 39 | 129 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed CMPX by 88.2 percentage points over the past year.
- Sutro Biopharma grew revenue faster in its latest fiscal year (+65.18% vs -100.00%).
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees
CMPX vs STRO FAQ
Which is bigger, Compass Therapeutics or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $142.77M compared with $123.94M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or STRO?
STRO returned +2.38% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.